Release Date: 19/07/12 11:20 Summary: Activities Report for the Quarter Ended 30 June 2012 Price Sensitive: Yes Download Document 1.58MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%